12:00 AM
May 23, 2016
 |  BioCentury  |  Finance

Herding an atypical syndicate

How Caribou aligned its series B syndicate with its CRISPR business areas

Unlike its gene editing peers that are going deep into therapeutics, Caribou Biosciences Inc. has been going wide, exploring numerous sectors where its CRISPR-Cas9 technology could be applied. With last week's $30 million series B round, Caribou has recruited a venture syndicate with expertise in the sectors where it wants to focus.

Caribou raised $11 million in a series A round in April 2015 and used the money to build out its platform, including wet labs and computational technologies.


Read the full 397 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >